Atomoxetine

Also known as: (R)-N-Methyl-3-phenyl-3-(o-tolyloxy)propan-1-amine

Active ingredient description

Atomoxetine is a highly selective and potent inhibitor of the pre-synaptic noradrenaline transporter, its presumed mechanism of action, without directly affecting the serotonin or dopamine transporters.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Atomoxetine
N Nervous system → N06 Psychoanaleptics → N06B Psychostimulants, agents used for ADHD and nootropics → N06BA Centrally acting sympathomimetics
Discover more medicines within N06BA09

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of Product Characteristics (SPC)
UK

Medicines

Atomoxetine is the active ingredient of these drugs:

Drug
Countries

Germany

Hong Kong

Spain

Austria Poland Romania

United Kingdom

Australia

Estonia Turkey

Hong Kong

Germany

South Africa

Turkey

South Africa

Austria Netherlands

Romania

Spain

Turkey

South Africa

Poland

South Africa

South Africa

Turkey

South Africa

South Africa

Australia Austria Canada Cyprus Ecuador

Structural formula

Graphic representation of the active ingredient's molecular structure

Chemical formula: C₁₇H₂₁NO
Molecular mass: 255.355 g/mol

External identifiers

CAS Substance: 83015-26-3
DrugBank Drug: DB00289
KEGG Drug: D07473
PubChem Compound: 54841
RxNorm Ingredient: 38400
SNOMED-CT Concept: 407037005
Atomoxetine (substance)
UNII Identifier: ASW034S0B8
ATOMOXETINE